Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
|Videos|November 30, 2016
Adapting to the New Value-Based Payment Models
Author(s)Deepak A. Kapoor, MD
Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.
Advertisement
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Status to LYT-200 Combo in High-Risk MDS
2
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
3
Looking Back on the Transformation of CLL Treatment: Jeff Sharman, MD
4
KRAS G12C as a Predictor of Immunotherapy Benefit in EMPOWER-Lung 1
5